Department of Gastroenterological Surgery, Kanazawa University, Kanazawa, Japan.
Department of Gastroenterological Surgery, Kanazawa University, Kanazawa, Japan
Anticancer Res. 2022 May;42(5):2783-2790. doi: 10.21873/anticanres.15758.
BACKGROUND/AIM: To evaluate the impact of prophylactic administration of pegfilgrastim in esophageal cancer (EC) patients treated with chemotherapy consisted of docetaxel, cisplatin, and fluorouracil (DCF).
Among 102 patients who received neoadjuvant or induction DCF for primary advanced EC, 65 received prophylactic pegfilgrastim and 37 did not. The association of pegfilgrastim with adverse events and clinicopathological outcomes was retrospectively analyzed.
In the pegfilgrastim group, the incidence of grade >3 neutropenia was lower (30.8% vs. 62.2%) and more patients avoided dose reduction or discontinuation of chemotherapy (32.3% vs. 70.3%). The radiological (PR≤) and histopathological (grade 1b≤) response rates were significantly higher (69.2% vs. 43.2% and 59.2% vs. 35.7%). Three-year overall survival and progression-free survival rates were significantly higher (65.0% vs. 48.6%, p=0.033; 56.1% vs. 35.1%, p=0.007, respectively).
Prophylactic pegfilgrastim in DCF may relieve adverse events and improve the oncologic outcome of EC patients.
背景/目的：评估预防性应用培非格司亭对接受多西他赛、顺铂和氟尿嘧啶（DCF）化疗的食管癌（EC）患者的影响。
在 102 例接受新辅助或诱导性 DCF 治疗原发性晚期 EC 的患者中，65 例接受了预防性培非格司亭治疗，37 例未接受。回顾性分析了培非格司亭与不良事件和临床病理结局的关系。
在培非格司亭组，≥3 级中性粒细胞减少症的发生率较低（30.8% vs. 62.2%），更多患者避免了化疗剂量减少或停药（32.3% vs. 70.3%）。影像学（PR≤）和组织病理学（1b 级≤）缓解率显著更高（69.2% vs. 43.2%和 59.2% vs. 35.7%）。3 年总生存率和无进展生存率显著更高（65.0% vs. 48.6%，p=0.033；56.1% vs. 35.1%，p=0.007）。
DCF 中预防性应用培非格司亭可减轻不良反应，改善 EC 患者的肿瘤学结局。
